BEAM
Price
$27.89
Change
+$0.02 (+0.07%)
Updated
Feb 3 closing price
Capitalization
2.83B
27 days until earnings call
Intraday BUY SELL Signals
RGNX
Price
$10.86
Change
-$1.31 (-10.76%)
Updated
Feb 3 closing price
Capitalization
549.77M
27 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BEAM vs RGNX

Header iconBEAM vs RGNX Comparison
Open Charts BEAM vs RGNXBanner chart's image
Beam Therapeutics
Price$27.89
Change+$0.02 (+0.07%)
Volume$1.21M
Capitalization2.83B
REGENXBIO
Price$10.86
Change-$1.31 (-10.76%)
Volume$701.88K
Capitalization549.77M
BEAM vs RGNX Comparison Chart in %
View a ticker or compare two or three
VS
BEAM vs. RGNX commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and RGNX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (BEAM: $27.89 vs. RGNX: $10.86)
Brand notoriety: BEAM and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 66% vs. RGNX: 82%
Market capitalization -- BEAM: $2.83B vs. RGNX: $549.77M
BEAM [@Biotechnology] is valued at $2.83B. RGNX’s [@Biotechnology] market capitalization is $549.77M. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 0 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • BEAM’s FA Score: 0 green, 5 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, BEAM is a better buy in the long-term than RGNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 3 TA indicator(s) are bullish while RGNX’s TA Score has 5 bullish TA indicator(s).

  • BEAM’s TA Score: 3 bullish, 6 bearish.
  • RGNX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, RGNX is a better buy in the short-term than BEAM.

Price Growth

BEAM (@Biotechnology) experienced а -9.15% price change this week, while RGNX (@Biotechnology) price change was -19.02% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.22%. For the same industry, the average monthly price growth was +3.03%, and the average quarterly price growth was +35.17%.

Reported Earning Dates

BEAM is expected to report earnings on Mar 03, 2026.

RGNX is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Biotechnology (-4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($2.83B) has a higher market cap than RGNX($550M). BEAM YTD gains are higher at: 0.613 vs. RGNX (-24.583). RGNX has higher annual earnings (EBITDA): -120M vs. BEAM (-434.55M). BEAM has more cash in the bank: 1.08B vs. RGNX (274M). RGNX has less debt than BEAM: RGNX (76.5M) vs BEAM (151M). RGNX has higher revenues than BEAM: RGNX (161M) vs BEAM (55.7M).
BEAMRGNXBEAM / RGNX
Capitalization2.83B550M515%
EBITDA-434.55M-120M362%
Gain YTD0.613-24.583-2%
P/E RatioN/AN/A-
Revenue55.7M161M35%
Total Cash1.08B274M392%
Total Debt151M76.5M197%
FUNDAMENTALS RATINGS
BEAM vs RGNX: Fundamental Ratings
BEAM
RGNX
OUTLOOK RATING
1..100
7457
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
73
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
4460
P/E GROWTH RATING
1..100
10022
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BEAM's Valuation (35) in the null industry is somewhat better than the same rating for RGNX (73) in the Biotechnology industry. This means that BEAM’s stock grew somewhat faster than RGNX’s over the last 12 months.

BEAM's Profit vs Risk Rating (100) in the null industry is in the same range as RGNX (100) in the Biotechnology industry. This means that BEAM’s stock grew similarly to RGNX’s over the last 12 months.

BEAM's SMR Rating (97) in the null industry is in the same range as RGNX (98) in the Biotechnology industry. This means that BEAM’s stock grew similarly to RGNX’s over the last 12 months.

BEAM's Price Growth Rating (44) in the null industry is in the same range as RGNX (60) in the Biotechnology industry. This means that BEAM’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's P/E Growth Rating (22) in the Biotechnology industry is significantly better than the same rating for BEAM (100) in the null industry. This means that RGNX’s stock grew significantly faster than BEAM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BEAMRGNX
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
86%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 14 days ago
76%
Bullish Trend 14 days ago
77%
Declines
ODDS (%)
Bearish Trend 8 days ago
83%
Bearish Trend 3 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
76%
Aroon
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
BEAM
Daily Signal:
Gain/Loss:
RGNX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MSDQX18.390.36
+2.00%
Morgan Stanley Emerging Mkt ex China A
AFNIX25.120.08
+0.32%
Bahl & Gaynor Income Growth I
KTRIX9.42-0.01
-0.11%
DWS Global Income Builder Inst
ADGIX25.59-0.32
-1.24%
AB Core Opportunities I
LEGCX49.32-0.94
-1.87%
Columbia Cornerstone Growth C

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
-0.11%
CRSP - BEAM
66%
Closely correlated
+1.34%
RXRX - BEAM
62%
Loosely correlated
-1.91%
NTLA - BEAM
62%
Loosely correlated
-0.08%
PRME - BEAM
61%
Loosely correlated
+0.26%
VIR - BEAM
58%
Loosely correlated
-0.39%
More

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with BEAM. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
+0.74%
BEAM - RGNX
57%
Loosely correlated
-0.11%
VYGR - RGNX
55%
Loosely correlated
-2.25%
BCYC - RGNX
54%
Loosely correlated
-7.55%
SYRE - RGNX
54%
Loosely correlated
+1.65%
XNCR - RGNX
54%
Loosely correlated
-0.99%
More